

SESSIONI FUORI CAMPO ECM

7 MARZO 2019

- 18.15 **From self-testing to self-managing: the OneTouch innovation in SMBG**
Simona Braghi (Sponsor LIFESCAN ITALIA)
- 18.30 **The role of vaccinations in patients with diabetes**
Carlo Bruno Giorda (Sponsor GLAXOSMITHKLINE)

8 MARZO 2019

- 17.30 **Nuovi approcci terapeutici nella gestione del diabete di tipo 2: ultime evidenze in tema di basalizzazione e moderne opportunità di intensificazione**
Iaiele Maria Bellone (Sponsor SANOFI)
- 17.45 **Semaglutide oltre l'efficacia glicometabolica: un possibile trattamento disease modifier per la malattia cardiovascolare nel diabete?**
Paola Ponzani (Sponsor NOVO NORDISK)

ORGANIZING AGENCY AND ECM PROVIDER

FMR s.r.l. – ID ECM 3726
Via C. Cattaneo, 106 - 41126 MODENA
Tel. 059-350201 - Fax 059-2922506 - Cell. 349-0725955
e-mail: mroncaglia@fmrweb.it

Provider Id: 3726 Event RES n° 245115 Edition n. 1
Credits (Italian CME): 17,1

Educational Goal: Implementation in daily routine of key issues and procedures of evidence based practice (EBM - EBN - EBP) (1)

Participants: 40 MD (cardiology, endocrinology, geriatrics, diabetes and metabolic diseases, internal medicine, nephrology).

PROMOTER

Chaira Medica Association
No-profit organization for the study of endocrine and metabolic disorders
Chieri (Turin) - Italy
medicachaira@gmail.com
www.chairamedica.it

SCIENTIFIC DIRECTOR

Carlo B. Giorda
Metabolism and Diabetes Unit, ASL TOS - Turin, Italy
carlogiordaposta@gmail.com

Con la sponsorizzazione non condizionante di



Con il Patrocinio di



Evento formativo nell'ambito della rete endocrino-diabetologica regionale

10th Post-graduate Updating Course

ADVANCES IN DIABETES, METABOLISM AND COMORBIDITIES

Associazione
Chaira Medica



Turin, Italy
March 7-9, 2019
Hotel NH Torino Centro
C.so Vittorio Emanuele, 104

Post-graduate Updating Course

This event is compliant with the Eucomed Code of Ethical Business Practice (www.ethicalmedtech.eu)

This is a highly interactive practical course. Appropriate space will be given to workgroups where participants will share knowledge and technical abilities to treat high risk patients. Diagnostic (lab, echo, echodoppler) and therapeutic options will be addressed. Experts will take part in the plenary discussions and give summary and conclusive presentations on the topics.

Target: Cardiologists, Endocrinologists, Geriatricians, Diabetologists, Internists and Nephrologists

Participation includes:

- Course attendance and training materials
- Certificate of attendance **issued after final examination**
- Continuous Medical Education (ECM) certification for Italian participants

FACULTY

Francesco Carlo Felicetti

SSD Unità di Transizione per Neoplasie Curate in Età Pediatrica
AOU Città della Salute e della Scienza - Torino

Paolo Fornengo

OU.O. Medicina Interna 3
Università di Torino - Torino

Marco Gallo

DUOC Endocrinologia Oncologica
AOU Città della Salute - Torino

Carlo Bruno Giorda

Direttore S.C. Malattie Metaboliche e Diabetologia
ASL TO 5 - Chieri (TO)

Roberta Manti

S.C. Malattie Metaboliche e Diabetologia
ASL TO 5 - Chieri (TO)

Paola Ponzani

U.O. Diabetologia
Osp. La Colletta ASL 3 Genovese
Arenzano (GE)

14.00	<i>Update on the course</i>
14.30	PLENARY SESSION AND OPENING LECTURE New directions for diabetes and metabolic disorders care (medications, FMG, CMG, CSII: pharma and technical innovation and outcome) <i>Speaker: C.B. Giorda, Turin (Italy)</i>
	SESSION 1 MANAGEMENT OF OBESITY: HEPATIC COMPLICATIONS <i>Teachers: C.B. Giorda</i>
15.30	<i>Outline the keypoints of management of obese patients' hepatic disorders. Study cases</i>
16.30	Discussion
17.15	<i>Conclusive presentation and State of the Art</i>
18.15	<i>End of session</i>

	SESSION 3 HOW TO HANDLE INNOVATION AND NEW DRUGS FOR METABOLIC DISORDERS <i>Teachers: C.B. Giorda, P. Ponzani</i>
13.30	<i>Use of SGLT2: from a study case to an update</i>
14.30	<i>New infos on GLP-1 RA and DPP4 inhibitors from a study case to an update</i>
15.30	<i>GLP-1 RA in combo therapy with insulin: from a study case to an update</i>
16.30	General discussion
17.30	<i>End of session</i>

DAY 2 – FRIDAY MARCH 8, 2019

DAY 3 – SATURDAY MARCH 9, 2019

	SESSION 2 FOCUS ON LIPIDS (WITH AND WITHOUT THYROID INTERFERENCE) AND HEART FAILURE <i>Teachers: P. Fornengo, R. Manti</i>	
8.30	<i>Outline the keypoints of lipid-lowering therapies with a focus on the role of thyroid. Study cases</i>	8.45
9.15	Discussion	9.15
10.00	<i>New pathways in management of lipid disorders: an update in the era of PCSK-9 inhibitors</i>	10.00
10.30	<i>Outline the keypoints of management of patients with heart failure and diabetes. Study cases</i>	10.45
10.45	Discussion	11.15
11.30	<i>Conclusive presentation and State of the Art</i>	12.00
12.30	Lunch	12.45
		13.00
	SESSION 4 DIABETES, METABOLISM AND ENDOCRINE DISORDERS ASSOCIATED WITH CANCER TREATMENT <i>Teachers: F.C. Felicetti, M. Gallo</i>	
	<i>Outline the keypoints of association between diabetes endocrine and cancer. Study cases</i>	
	Discussion	
	<i>Conclusive presentation and State of the Art</i>	
	<i>Outline the keypoints of residual cardiovascular and endocrine risk following oncologic treatments (cancer survival). Study cases</i>	
	Discussion	
	<i>Conclusive presentation and State of the Art</i>	
	<i>ECM questionnaire</i>	
	Lunch	